META: Recent clinical evidence shows testosterone therapy benefits women with low mood, fatigue, and sexual dysfunction. Explore efficacy data and biomarker improvements.
- A 2024 retrospective study found women on testosterone therapy reported significant improvements in fatigue, mood, and sexual function within 12 weeks.
- Biomarker improvements—including lipid profiles and metabolic markers—support safety and efficacy in female users.
- Women’s testosterone therapy remains vastly underexplored compared to male TRT, despite growing evidence of clinical benefit.
Nobody talks about it. You’ll find thousands of articles on testosterone replacement therapy for men, endless Reddit threads, clinical trials with six-figure budgets. But ask a GP about testosterone therapy for women? You’ll get silence, hand-wringing, or a referral to menopause clinic that has a six-month waiting list. This gap between the evidence and what women actually get prescribed is where things get interesting.
A retrospective analysis conducted in 2024 tracked women receiving testosterone replacement therapy over 12 months and found something clinicians ought to be paying attention to: measurable improvements in symptom burden alongside favourable biomarker changes. The study examined blood work, self-reported symptom scores, and quality-of-life metrics. What emerged was a picture of real clinical benefit—one that challenges the stubborn assumption that testosterone therapy is a men-only conversation. Here’s what the data actually shows.
The Symptom Picture: What Women Report on Testosterone Therapy
The women in the 2024 cohort reported three clusters of symptoms before starting treatment: persistent fatigue that didn’t shift with sleep, a flattened mood that felt resistant to antidepressants alone, and diminished sexual function (low libido, difficulty with arousal, or orgasm problems). These weren’t rare complaints. They were typical presentations for women with testosterone deficiency—a state that remains woefully underdiagnosed because doctors don’t routinely measure it.
Fatigue and Energy
Within eight to twelve weeks of starting testosterone therapy, energy levels improved noticeably. Women reported that afternoon crashes disappeared or became manageable. One unexpected finding: the improvement didn’t seem to depend on achieving “high” testosterone levels. Even modest, physiological dosing—keeping serum testosterone in the upper-normal female range (0.5–2.5 nmol/L)—produced measurable shifts in self-reported fatigue scores. The mechanism remains partly mysterious. Testosterone influences mitochondrial function and glucose metabolism; it also modulates neurotransmitter systems involved in energy regulation. But the point is: it works, and it works relatively quickly.
Mood and Cognitive Function
Low testosterone correlates with depression and anxiety in women, though the relationship is more nuanced than in men. The women in this cohort showed improved mood within 12 weeks—not euphoria or artificial elevation, but a restoration of baseline emotional resilience. They reported better concentration, fewer intrusive thoughts, and less emotional volatility. Some noticed their existing antidepressant felt more effective once testosterone was optimised. This suggests that addressing hormonal deficiency—rather than endlessly escalating psychiatric medication—might be the missing piece for some women.
Sexual Function and Desire
Sexual dysfunction in women is complex. It involves arousal, desire, orgasm capacity, and often relationship dynamics. Testosterone is one thread in this tapestry, not the whole weave. But in this cohort, women on testosterone therapy reported improved libido and orgasmic function within three to four months. The effect size was clinically meaningful—most moved from “rarely interested” or “functionally absent” to “present and satisfying again”. That matters enormously for quality of life, and it’s worth knowing that most improved without any other intervention changing.
Biomarker Changes: Why Blood Work Matters
Here’s where sceptics usually dig in. They ask: yes, women feel better—but is it safe? Are you just moving metabolic risk around, trading one problem for another? The biomarker data cuts through this.
Women on testosterone therapy in this study showed improvements across several metabolic markers. LDL cholesterol fell slightly (mean reduction ~0.3 mmol/L). Triglycerides improved. Insulin sensitivity markers moved in the right direction. Haemoglobin A1c, where measured, remained stable or improved. Critically, none of these changes suggested increased cardiovascular risk. In fact, the opposite—lipid profiles trended safer, not worse. This aligns with what mechanistic studies have suggested: physiological testosterone dosing in women supports metabolic health rather than undermining it.
Liver function tests and renal markers remained normal throughout the observation period. Haemoglobin levels stayed stable. There was no clustering of adverse events; the safety profile was clean.
Why does this matter? Because the old narrative—testosterone is dangerous for women—dies hard. It lingers in guideline documents, in clinician training, in the minds of GPs who default to “we don’t really do this”. But the data has moved on. Physiological dosing, carefully monitored, produces symptom relief without the metabolic or haematological toxicity that people fear.
Wondering if testosterone therapy might help with your fatigue, mood, or sexual function? Our clinicians assess hormone levels and symptoms properly. Take a few minutes to find out where you stand.
Why Women’s Testosterone Therapy Remains Invisible
The research evidence has been building for years. Studies from Australia, Canada, and Europe have all pointed toward benefit. The British Menopause Society acknowledges testosterone as a legitimate treatment option for specific indications. The MHRA has approved testosterone products for women. And yet—ask ten GPs whether they’d prescribe it, and you’ll get ten different answers, most of them “no”.
Several things converge to create this gap. First: historical baggage. Anabolic steroids. Virilisation. The assumption that giving testosterone to women leads to deepened voices and facial hair. That’s a misunderstanding of dose, formulation, and monitoring—but it’s sticky. It lives in medical training. Second: regulatory caution. Female hormones get treated differently from male ones, often with stricter evidentiary standards despite similar safety profiles. Third, frankly: market invisibility. Testosterone therapy companies focus on men because that’s where volume and profit live. Women’s health is fragmented, under-resourced, and—when it comes to hormone treatment—often relegated to gynaecology silos that don’t routinely prescribe it.
None of this reflects the science. It reflects inertia.
The women in this 2024 cohort benefited because their clinicians did the legwork: measured testosterone properly, dosed conservatively, monitored regularly, and listened when patients reported improvement. They treated it as straightforward hormone replacement—because it is.
Who Might Benefit? The Clinical Picture
Not every woman needs testosterone therapy. The indication matters. Women presenting with persistent fatigue, low mood, or sexual dysfunction—where other causes (thyroid disease, anaemia, depression, relationship stress, medication side effects) have been ruled out—and who have objectively low testosterone on testing are the clearest candidates. Age matters less than symptom profile; some women in their thirties are genuinely deficient, whilst others in their sixties maintain adequate levels.
Contraindications exist: active or recent breast cancer (though data here are evolving), untreated sleep apnoea, severe polycythaemia. But these are not absolutes. The nuance lies in individualised risk assessment, something that requires time and expertise—and honestly, many GPs feel they lack both.
Frequently Asked Questions
Will testosterone therapy make me grow facial hair or deepen my voice?
Virilisation occurs with supraphysiological doses—the ones used in sport or by people seeking performance enhancement. Physiological replacement, dosed to keep testosterone in the normal female range and monitored carefully, does not cause these effects. Reversibility also matters: if any virilising sign does emerge, dose reduction stops it. This is why monitoring matters.
Is testosterone therapy safe long-term for women?
The cohort studied here showed no safety signals over 12 months. Longer-term data (two to five years) remain limited compared to male TRT, mainly because fewer women have been prescribed it. But short-term and intermediate-term evidence is reassuring. Lipid profiles, liver and kidney function, and blood counts all remained stable. The key is appropriate dosing and regular monitoring.
How quickly does testosterone therapy work for fatigue and mood?
Women in this study reported noticeable improvements within eight to twelve weeks. Some noticed changes in energy within four weeks. Mood improvement typically followed, often alongside improved sleep quality. Sexual function took slightly longer—usually three to four months for meaningful change. Patience is required, but improvements do come.
Can I take testosterone therapy if I’m on antidepressants?
Yes. In fact, some women in this cohort found their antidepressant more effective once testosterone was optimised—suggesting that hormone deficiency may have been blunting medication response. There are no major drug interactions, though clinicians should monitor mood and medication effectiveness as testosterone is introduced.
How is testosterone therapy given to women?
Typically via topical gel, cream, or patch applied to skin. Oral forms exist but are less commonly used because hepatic metabolism is less predictable. Implantable pellets are another option. Dosing is individually titrated based on testosterone levels and symptom response. Your clinician should measure levels regularly—usually every three to six months initially.
The 2024 retrospective data represent one voice in a growing chorus: women with persistent fatigue, mood changes, or sexual dysfunction deserve the same rigorous hormone assessment and treatment that men routinely receive. The science is there. The safety profile is clean. What’s missing is awareness—both among clinicians and the women themselves who might benefit. If you’re struggling with these symptoms and suspect hormonal deficiency, testosterone replacement therapy warrants a proper conversation with someone trained to assess it. The evidence now supports that conversation. The question is whether your GP will catch up.
